UBS Group’s Albireo Pharma Inc ALBO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-6,164
| Closed | -$133K | – | 11354 |
|
|
2022
Q4 | $133K | Buy |
6,164
+5,399
| +706% | +$114K | ﹤0.01% | 5827 |
|
|
2022
Q3 | $15K | Buy |
765
+359
| +88% | +$7.42K | ﹤0.01% | 7875 |
|
|
2022
Q2 | $8K | Sell |
406
-40,892
| -99% | -$1.08M | ﹤0.01% | 8411 |
|
|
2022
Q1 | $1.23M | Buy |
41,298
+25,796
| +166% | +$755K | ﹤0.01% | 3885 |
|
|
2021
Q4 | $361K | Buy |
15,502
+14,882
| +2,400% | +$396K | ﹤0.01% | 5236 |
|
|
2021
Q3 | $19K | Buy |
620
+20
| +3% | +$619 | ﹤0.01% | 7249 |
|
|
2021
Q2 | $21K | Sell |
600
-27,401
| -98% | -$891K | ﹤0.01% | 7296 |
|
|
2021
Q1 | $987K | Buy |
28,001
+27,911
| +31,012% | +$1.03M | ﹤0.01% | 4260 |
|
|
2020
Q4 | $3K | Sell |
90
-5,214
| -98% | -$190K | ﹤0.01% | 8045 |
|
|
2020
Q3 | $177K | Buy |
5,304
+1,032
| +24% | +$30.1K | ﹤0.01% | 4861 |
|
|
2020
Q2 | $113K | Sell |
4,272
-3,093
| -42% | -$73K | ﹤0.01% | 5212 |
|
|
2020
Q1 | $121K | Sell |
7,365
-9,042
| -55% | -$199K | ﹤0.01% | 5123 |
|
|
2019
Q4 | $417K | Buy |
16,407
+6,445
| +65% | +$129K | ﹤0.01% | 4999 |
|
|
2019
Q3 | $199K | Buy |
9,962
+7,093
| +247% | +$184K | ﹤0.01% | 5257 |
|
|
2019
Q2 | $93K | Buy |
2,869
+2,844
| +11,376% | +$95.1K | ﹤0.01% | 5430 |
|
|
2019
Q1 | $1K | Sell |
25
-3,329
| -99% | -$89.6K | ﹤0.01% | 7594 |
|
|
2018
Q4 | $82K | Sell |
3,354
-11,151
| -77% | -$295K | ﹤0.01% | 5711 |
|
|
2018
Q3 | $478K | Buy |
14,505
+3,287
| +29% | +$108K | ﹤0.01% | 4444 |
|
|
2018
Q2 | $398K | Buy |
11,218
+2,077
| +23% | +$67.3K | ﹤0.01% | 4485 |
|
|
2018
Q1 | $298K | Hold |
9,141
| – | – | ﹤0.01% | 4521 |
|
|
2017
Q4 | $234K | Buy |
+9,141
| New | +$232K | ﹤0.01% | 4805 |
|
|
2017
Q3 | – | Sell |
-1
| Closed | – | – | 8101 |
|
|
2017
Q2 | $0 | Sell |
1
-244
| -100% | -$5.01K | ﹤0.01% | 8096 |
|
|
2017
Q1 | $6K | Buy |
245
+244
| +24,400% | +$5.31K | ﹤0.01% | 6930 |
|
|
2016
Q4 | $0 | Sell |
1
-929
| -100% | -$19.3K | ﹤0.01% | 8136 |
|
|
2016
Q3 | $12K | Buy |
930
+918
| +7,650% | +$10.8K | ﹤0.01% | 6676 |
|
|
2016
Q2 | $0 | Sell |
12
-559
| -98% | -$6.16K | ﹤0.01% | 8056 |
|
|
2016
Q1 | $6K | Buy |
571
+174
| +44% | +$1.55K | ﹤0.01% | 6951 |
|
|
2015
Q4 | $4K | Buy |
397
+385
| +3,208% | +$3.98K | ﹤0.01% | 7801 |
|
|
2015
Q3 | $0 | Sell |
12
-416
| -97% | -$10.5K | ﹤0.01% | 8726 |
|
|
2015
Q2 | $13K | Buy |
428
+350
| +449% | +$11.8K | ﹤0.01% | 7274 |
|
|
2015
Q1 | $3K | Sell |
78
-54
| -41% | -$2.28K | ﹤0.01% | 8359 |
|
|
2014
Q4 | $6K | Buy |
+132
| New | +$5.79K | ﹤0.01% | 8873 |
|
Other funds holding ALBO
UBS Group's ALBO Position: Q1 2023 in Review
UBS Group sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 6,164 shares — an estimated $133K sold.
UBS Group first reported a position in ALBO in Q4 2014 and held it in 32 quarters. The position peaked at $1.23M in Q1 2022. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.
- UBS Group reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
- UBS Group sold 6,164 Albireo Pharma Inc shares in Q1 2023, an estimated $133K.
- UBS Group first reported a position in Albireo Pharma Inc in Q4 2014 and held it in 32 quarters.
- UBS Group's Albireo Pharma Inc position peaked at $1.23M in Q1 2022.
- 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.
Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.